WallStreetZenWallStreetZen

NASDAQ: ACRV
Acrivon Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ACRV

Based on 4 analysts offering 12 month price targets for Acrivon Therapeutics Inc.
Min Forecast
$14.00+32.83%
Avg Forecast
$16.50+56.55%
Max Forecast
$20.00+89.75%

Should I buy or sell ACRV stock?

Based on 4 analysts offering ratings for Acrivon Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ACRV stock forecasts and price targets.

ACRV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-05
lockedlocked$00.00+00.00%2024-04-01
lockedlocked$00.00+00.00%2024-04-01
lockedlocked$00.00+00.00%2024-03-28

1 of 1

Forecast return on equity

Is ACRV forecast to generate an efficient return?

Forecast return on assets

Is ACRV forecast to generate an efficient return on assets?

ACRV revenue forecast

What is ACRV's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$3.1M
Avg 2 year Forecast
$23.9M
Avg 3 year Forecast
$75.9M

ACRV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACRV$10.54$16.50+56.55%Strong Buy
INO$10.20$21.00+105.88%Buy
TSVT$4.64$11.67+151.44%Buy
PBYI$4.99$7.00+40.28%Buy
XBIT$7.91N/AN/A
View Top Biotech Stocks

Acrivon Therapeutics Stock Forecast FAQ

Is Acrivon Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ACRV) stock is to Strong Buy ACRV stock.

Out of 4 analysts, 1 (25%) are recommending ACRV as a Strong Buy, 3 (75%) are recommending ACRV as a Buy, 0 (0%) are recommending ACRV as a Hold, 0 (0%) are recommending ACRV as a Sell, and 0 (0%) are recommending ACRV as a Strong Sell.

If you're new to stock investing, here's how to buy Acrivon Therapeutics stock.

What is ACRV's revenue growth forecast for 2025-2027?

(NASDAQ: ACRV) Acrivon Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Acrivon Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ACRV's revenue for 2025 to be $69,948,179, with the lowest ACRV revenue forecast at $69,948,179, and the highest ACRV revenue forecast at $69,948,179. On average, 4 Wall Street analysts forecast ACRV's revenue for 2026 to be $541,068,403, with the lowest ACRV revenue forecast at $9,054,780, and the highest ACRV revenue forecast at $1,186,176,232.

In 2027, ACRV is forecast to generate $1,717,148,555 in revenue, with the lowest revenue forecast at $101,866,280 and the highest revenue forecast at $3,351,853,335.

What is ACRV's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: ACRV) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ACRV's Price Target?

According to 4 Wall Street analysts that have issued a 1 year ACRV price target, the average ACRV price target is $16.50, with the highest ACRV stock price forecast at $20.00 and the lowest ACRV stock price forecast at $14.00.

On average, Wall Street analysts predict that Acrivon Therapeutics's share price could reach $16.50 by Apr 5, 2025. The average Acrivon Therapeutics stock price prediction forecasts a potential upside of 56.55% from the current ACRV share price of $10.54.

What is ACRV's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: ACRV) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.